Among all KRAS mutant NSCLC, the immunotherapy group compared to chemotherapy group had higher ORR (44.00% vs 30.43%) and DCR (96.00% vs 80.00%). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.